title: Efficacy of antiviral agents in feline herpetic keratitis: results of an in vitro study.
abstract: OBJECTIVE
  To determine, by a plaque reduction assay, the in vitro efficacy of novel antiviral agents in the treatment of feline herpes virus 1 (FHV-1) keratitis in the domestic cat (Felis felis).
  
  
  METHODS
  A standard plaque reduction assay was performed using a laboratory strain of FHV-1 and embryo-derived feline kidney cells to determine the in vitro efficacy of the antiviral drugs penciclovir (PCV), bromovinyldeoxyuridine (BVdU), and (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl) adenine (HPMPA) and to compare these with the drugs acyclovir (ACV) and trifluorothymidine (TFT). Efficacy was assessed by determining the dose of drug at which 50% plaque reduction was noted (ED(50)).
  
  
  RESULTS
  HPMPA was found to have greatest antiviral activity (ED(50) 0.07 microg/ml). ACV was least active (ED(50) 24 microg/ml), while TFT was active with an ED(50) of 5.7 microg/ml. PCV and BVdU had intermediate activity (ED(50) 1.6 and 1.7 microg/ml, respectively).
  
  
  CONCLUSIONS
  This study suggests that the efficacy of HPMPA, BVdU, and penciclovir in cats with herpesviral keratitis should be determined in vivo as their efficacy in vitro was substantially greater than that of acyclovir, already shown to have demonstrable but limited clinical antiviral activity.
authors.affiliation: Department of Clinical Veterinary Medicine, University of Cambridge, Madingley Road, Cambridge, United Kingdom. doctordlwilliams@aol.com
authors.forename: D L
authors.initials: DL
authors.lastname: Williams
authors.forename: T
authors.initials: T
authors.lastname: Fitzmaurice
authors.forename: L
authors.initials: L
authors.lastname: Lay
authors.forename: K
authors.initials: K
authors.lastname: Forster
authors.forename: J
authors.initials: J
authors.lastname: Hefford
authors.forename: C
authors.initials: C
authors.lastname: Budge
authors.forename: K
authors.initials: K
authors.lastname: Blackmore
authors.forename: J C
authors.initials: JC
authors.lastname: Robinson
authors.forename: H F
authors.initials: HF
authors.lastname: Field
mesh_terms: D000212:Acyclovir / Q000031:analogs & derivatives* / Q000494:pharmacology; D000225:Adenine / Q000031:analogs & derivatives* / Q000494:pharmacology; D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001973:Bromodeoxyuridine / Q000494:pharmacology; D002371:Cat Diseases / Q000188:drug therapy* / Q000821:virology*; D002415:Cats; D002478:Cells, Cultured; D006147:Guanine; D016849:Keratitis, Herpetic / Q000188:drug therapy / Q000662:veterinary* / Q000821:virology*; D063065:Organophosphonates / Q000494:pharmacology; D014271:Trifluridine / Q000494:pharmacology; D010948:Viral Plaque Assay / Q000592:standards*
chemical_list: D000998:Antiviral Agents; D063065:Organophosphonates; C053539:penciclovir; D006147:Guanine; C050127:9-(S)-(3-hydroxy-2-(phosphonomethoxy)propyl)adenine; D001973:Bromodeoxyuridine; D000225:Adenine; D014271:Trifluridine; D000212:Acyclovir